What's New at LRI
What the Doctors Are Saying about the Success of the Benlysta Trial.
And What Do You Have to Add?
The world of lupus is abuzz with news of the first large-scale Phase 3 lupus drug trial in decades to show effectiveness, improving quality of life and suppressing disease activity in a significant number of patients.
Wondering What the Lupus Experts Are Saying?
Around the nation
- Richard Furie, MD, chief of the division of rheumatology and allergy-clinical rheumatology at North Shore-LIJ Health System in New York
“Benlysta is the first ‘targeted biological agent’ developed specifically for systemic lupus that has the potential to obtain FDA approval…HGS took a very ambitious development approach—huge international concurrent trials which represent a large investment in systemic lupus therapy."
- Tammy O. Utset, MD, MPH, associate professor of medicine at the University of Chicago
"Everybody was getting a little discouraged….It's very exciting to finally have a trial in lupus showing efficacy.”
- Betty Diamond, MD chief of the autoimmune disease center at North Shore-LIJ Health System in New York told the
"There are several exciting contributions of this new study [including that] the treatment was safe, in that there were no more serious health problems in the Benlysta group than in the placebo group. And the Benlysta study shows the desire of people with SLE to find better treatments: 865 participated in this trial. Without them, none of these findings would have been possible."
- Bevra Hahn, MD, professor of medicine at the University of California
About the LRI
Lupus Research Institute